| Document |
Document Title |
|
WO/2023/197952A1 |
Provided are a yeast extract with high base and base derivative contents and a method for preparing same. The yeast extract with high base and base derivative contents provided herein comprises 20000-40000 mg/kg of bases and base derivat...
|
|
WO/2023/191452A1 |
An improved method of producing gamma-butyrolactone (GBL) product with high purity in high yield from a starting biomass containing poly-4-hydroxybutyrate (P4HB) and water is disclosed. The method includes recycling a part of GBL product...
|
|
WO/2023/185184A1 |
Provided are monoamine oxidase and an application thereof in a biocatalytic method.
|
|
WO/2023/184724A1 |
Disclosed in the present invention are an antimycin compound as well as a preparation method therefor and the use thereof. The compound is characterized in that the compound is separated from a secondary metabolite of marine actinomycete...
|
|
WO/2023/182610A1 |
The present invention relates to a method for mass production of fulvic acid from humus soil. A method for extracting fulvic acid from humus soil according to the present invention employs at least one enzyme selected from the group cons...
|
|
WO/2023/183543A1 |
Disclosed is a method for forming selenoneine or analogs thereof. The method may include phosphorylating sodium selenide to a selenophosphate, using adenosine triphosphate (ATP) and at least a first protein, generating a selenosugar by c...
|
|
WO/2023/175351A1 |
The present invention relates to the genetic engineering of biotin-expressing cells, and to the enzyme engineering of biotin synthase (bioB), to enhance D-biotin biosynthesis. The invention also provides optimised methods of culturing th...
|
|
WO/2023/174511A1 |
The present invention relates in a first aspect to an enzymatic method for the production of an L-glufosinate P-ester. This method is characterized by a step (c) in which an L-glufosinate P-ester carbamoylate is reacted to give the corre...
|
|
WO/2023/175002A1 |
The present invention relates to crosslinked enzyme aggregates (CLEAs) with beneficial properties, and to methods for their preparation. The present invention also pertains to membrane microreactors and microfluidic systems containing su...
|
|
WO/2023/173058A2 |
The present invention provides novel biocatalysts and associated methods of use for the oxidative desymmetrization of fused bicyclic proline analogues to produce APIs and intermediates. The novel biocatalysts of the present disclosure ar...
|
|
WO/2023/169184A1 |
Provided are engineered transaminase polypeptides for the synthesis of Ubrogepant intermediates with high stereoselectivity, high catalytic activity and good stability. Also provided is a reaction process for the asymmetric synthesis of ...
|
|
WO/2023/169071A1 |
A monoamine oxidase and the use thereof in a biocatalytic method.
|
|
WO/2023/170694A1 |
The present invention provides a transgenic Helichrysum umbraculigerum (Less.) cell, tissue, or plant, comprising an artificial DNA molecule. Further provided are a method for producing the transgenic H. umbraculigerum (Less.) cell, tiss...
|
|
WO/2023/168272A2 |
The disclosure relates to flavin-dependent oxidases having cannabinoid synthase activity. The flavindependent oxidase comprises: (i) a first amino acid sequence comprising a His residue, wherein an FAD cofactor is covalently attached to ...
|
|
WO/2023/168277A2 |
The present disclosure provides an in vitro method for producing a cannabinoid, the method comprising reacting a prenylated aromatic compound with a flavin-dependent oxidase in a reaction mixture to form the cannabinoid, wherein the flav...
|
|
WO/2023/168266A2 |
The present disclosure relates to a non-natural flavin-dependent oxidase that does not comprise a disulfide bond and that is capable of oxidative cyclization of a prenylated aromatic compound into a cannabinoid. In some embodiments, the ...
|
|
WO/2023/161230A1 |
The present invention concerns glycosyltransferase enzyme mutants having improved half-lives and thermal stability compared to the parent enzyme UDP-glycosyltransferase (PtUGT) from the indigo producing plant Polygonum tinctorium/Persica...
|
|
WO/2023/158722A2 |
The present disclosure encompasses a process for chiral resolution of racemic amines, particularly ethyl 2-(4-((tert-butoxycarbonyl)amino)phenyl)piperidine-3-carboxy
late, into its desired isomer, ethyl (2R,3S)-2-(4-((tert-butoxycarbonyl...
|
|
WO/2023/151894A1 |
The present application provides a process for the preparation of α-methylene-γ-butyrolactone, said process comprising the steps of: a) acetylating the C1-hydroxyl group of isoprenol to yield isoprenyl acetate; b) forming 4-acetoxy-2-m...
|
|
WO/2023/146181A1 |
The present invention provides Chlorella vulgaris H92 (Chlorella vulgaris H92)(KCTC 14843BP) having heme precursor production ability. In addition, the present invention provides a method for preparing a chlorella bacterial body or a foo...
|
|
WO/2023/138679A1 |
Provided is a method for synthesizing a flavonoid compound. The method comprises providing a recombinant prokaryotic cell, wherein, in the prokaryotic cell, the transmembrane protein rhodanese Ygap of Escherichia coli is up-regulated or ...
|
|
WO/2023/133490A1 |
Aspects of the disclosure relate to modified skin commensal bacterial host cells capable of producing terpenes.
|
|
WO/2023/130191A1 |
This disclosure relates to recombinant microbes, systems, and methods useful in the production of psilocybin and dimethyltryptamine (DMT). The disclosure relates to modifications and optimizations to genes and enzymes directly involved i...
|
|
WO/2023/130076A2 |
This disclosure relates generally to non-naturally organisms, as well as compositions and methods thereof, which host biosynthetic pathways that can produce novel or rare alkaloids. In some embodiments, the non-naturally occurring organi...
|
|
WO/2023/123589A1 |
Disclosed are a transaminase mutant and the use thereof, wherein the transaminase mutant has a sequence formed after an amino acid mutation occurs in the sequence shown in SEQ ID NO: 1, wherein the site at which the amino acid mutation o...
|
|
WO/2023/130078A2 |
This disclosure provides non-naturally occurring organisms with genetic modifications that are useful for producing desirable alkaloids. This disclosure also provides methods of making and analysing non-naturally occurring organisms that...
|
|
WO/2023/125373A1 |
A method for preparing ruxolitinib intermediates, i.e. (R)-3-(4-halo-1H-pyrazol-1-yl)-3-cyclopentylpropionate (VI) and (R)-3-(4-halo-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile (IX). In the method, 3-(4-halo-1H-pyrazol-1-yl)-3-cyclopent...
|
|
WO/2023/130075A2 |
This disclosure provides genetically engineered organisms with genetic modifications that are useful for producing desirable alkaloids. This disclosure also provides methods of making genetically engineered organisms that can produce des...
|
|
WO/2023/118401A1 |
The present invention relates to a method for preparing a composition containing a biomass of microorganisms, said preparation method comprising the recovery of phytotoxins from a fermentation juice obtained from culturing phytotoxin-pro...
|
|
WO/2023/122251A2 |
The present disclosure relates to microbial hosts, enzymes, and methods for biosynthesis of lactones.
|
|
WO/2023/106464A1 |
The present invention provides a novel diphenazine compound or an enantiomer or pharmaceutically acceptable salt thereof. A novel diphenazine compound or an enantiomer or pharmaceutically acceptable salt thereof according to the present ...
|
|
WO/2023/106452A1 |
The present invention relates to a novel xanthone compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof, the xanthone compound exhibiting cytotoxicity against a cancer cell line so as to inhibit cell growth, t...
|
|
WO/2023/108169A2 |
A novel yeast strain and methods of use thereof for robust biosynthesis of demethylated polymethoxy flavones are disclosed. Also provided are method of administering demethylated polymethoxy flavones for the treatment of obesity and infl...
|
|
WO/2023/067043A9 |
Improved methods of making amberketal and amberketal homologues and compositions comprising same, improved squalene-hopene cyclase (SHC) enzymes to be used in said methods, nucleic acid constructs and vectors encoding said enzymes, and h...
|
|
WO/2023/101349A1 |
The present invention relates to a novel Enterococcus faecium LCM001 strain, and a use thereof. A culture medium of the novel Enterococcus faecium LCM001 strain (deposit number: KCTC 14669BP) according to the present invention can suppre...
|
|
WO/2022/109194A9 |
Methods and engineered cells are provided for increasing activity of a norcoclaurine synthase in a microbial cell. The method comprises, within the engineered microbial cell, contacting an engineered norcoclaurine synthase with a substra...
|
|
WO/2023/092547A1 |
A smart cell factory of a high value-added metabolite constructed on the basis of automation technology, which belongs to the technical field of metabolic engineering. According to the present invention, a key enzyme mutant gene with a h...
|
|
WO/2023/088098A1 |
Provided are a dehydrogenase mutant L283V/L286V and a preparation method therefor and an application thereof. The amino acid sequence of the mutant L283V/L286V is as shown in SEQ ID NO: 1; or leucine at position 283 and position 286 of d...
|
|
WO/2023/085874A1 |
The present application relates to a polypeptide variant having biotin synthase activity capable of enhancing biotin production ability, a recombinant microorganism with excellent biotin production ability prepared by introducing the var...
|
|
WO/2023/085954A1 |
Biosensor systems for detecting levels of nitrogen-containing molecules are provided. Further provided are biosensor system components and various detection platforms, methods, and kits.
|
|
WO/2023/085875A1 |
The present application relates to a microorganism or a biotin production method using same, the microorganism having reduced activity of class II type, intrinsic BirA and comprising class I type BirA.
|
|
WO/2023/081842A2 |
Provided are methods, prokaryotic host cells, expression vectors, and kits for the production of psilocybin or an intermediate or a side product thereof. In certain embodiments, the prokaryotic host cell is selected from the group consis...
|
|
WO/2023/077817A1 |
Provided is a method for synthesizing pro-xylane by using a chemical enzymatic method, comprising: S1) mixing an acetylacetone or acetoacetate compound, xylose and an alkaline substance in a solvent, and heating to react, so as to obtain...
|
|
WO/2023/081833A1 |
Provided is a method for the production of psilocybin or an intermediate or a side product thereof comprising: contacting a prokaryotic host cell with one or more expression vectors, wherein each expression vector comprises a psilocybin ...
|
|
WO/2023/081829A2 |
Provided are methods, prokaryotic host cells, expression vectors, and kits for the production of psilocybin or an intermediate or a side product thereof using at least one psilocybin production gene from Psilocybe cyanescens, Panaeolus c...
|
|
WO/2023/067044A1 |
The disclosure relates to sesquiterpene homologues, their use as fragrance and a method of their production.
|
|
WO/2023/068703A1 |
The present invention relates to a method for producing durumamide A. Durumamide A can be produced at high yield by using an extraction method using Corynebacterium durum according to an embodiment of the present invention and a syntheti...
|
|
WO/2023/069575A1 |
The present invention provides methods for producing psychoactive substances by culturing cells derived from tissues or organs of animals that produce psychoactive substances.
|
|
WO/2023/063585A1 |
The present invention relates to a pharmaceutical composition for preventing or treating inflammation disease and a food for alleviating inflammation, both comprising Antarctic fungi-derived metabolites and, more specifically, to a pharm...
|
|
WO/2023/061391A1 |
An Ansamitocin fermentation method, comprising fermentation culture and daily flow supplementation starting from the fermentation culture, wherein a supplement added by the daily flow supplementation comprises, in mass-volume ratio, 30-6...
|
